Duloxetine, the investigative serotonin norepinephrine reuptake inhibitor (SNRI), is safe and well tolerated at a dose range of 40 to120mg/day BID, researchers reported at the annual meeting of the American College of Clinical Pharmacology (ACCP).
In addition, trial results show that duloxetine did not prolong the QT interval or display any treatment- related increases in hypertension, reported Dr. Michael Detke, lead researcher and clinical investigator at Lilly Research Laboratories in Indianapolis, Indiana.
The investigators conducted a meta-analysis of seven double-blind, placebo-controlled trials. Six of the trials were for major depressive disorder. The 1,032 (759 female) duloxetine subjects and the 723 (534 female) placebo subjects had a mean age of 43 years (both male and female) and mean weight of 81 kg. All met DSM-IV criteria for major depressive disorder.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!